<DOC>
	<DOCNO>NCT00306072</DOCNO>
	<brief_summary>The purpose study evaluate two level herbal extract Salacia oblonga ( salacinol ) postprandial glycemia insulinemia patient Type 2 diabetes ingestion high-carbohydrate control meal .</brief_summary>
	<brief_title>Effect Different Doses Salacinol Extract Glycemic Insulinemic Response Patients With Type 2 Diabetes</brief_title>
	<detailed_description>Although generate good quantity animal human data salacinol extract , explore effect salacinol extract postprandial glycemia insulinemia patient type 2 diabetes . We plan study 66 patient diabetes multicenter , randomize , double-blind , three-treatment , crossover study . While fasted state , subject consume one follow three meal : standard liquid meal contain 110 g carbohydrate , 18 g protein , 12 g fat , 620 kilocalorie ( Control ) ; Control plus 240 mg Salacia oblonga extract ; Control plus 480 mg Salacia oblonga extract . Postprandial serum glucose serum insulin sample analyze 180 min .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<criteria>1 . Subject type 2 diabetes mellitus verify prescription oral antihyperglycemic medication . 2 . Subject 18 75 year age , inclusively . 3 . Subject male nonpregnant , nonlactating female , least six week postpartum . A urine pregnancy test require female subject unless subject hysterectomy , tubal ligation , &gt; 2 year postmenopausal . 4 . Subject body mass index ( BMI ) 18 35 kg/m2 . 5 . Subject voluntarily sign date informed consent form , approve Independent Ethics Committee/Institutional Review Board provide HIPAA ( applicable privacy regulation ) authorization prior participation study . 1 . Subject use exogenous insulin glucose control . 2 . Subject state he/she infection ( require medication hospitalization ) . 3 . Subject state he/she current hepatic disease . 4 . Subject state he/she surgery , corticosteroid treatment last 3 month antibiotic last 3 week . 5 . Subject firstdegree relative enrol current study . 6 . Subject state he/she active malignancy ( subject cutaneous malignancy , melanoma , may include study ) . 7 . Subject state he/she significant cardiovascular event &lt; 12 week prior study entry . 8 . Subject state he/she end stage organ failure , include clinically advanced renal disease assess study physician . 9 . Subject state he/she status postorgan transplantation . 10 . Subject state he/she chronic , contagious , infectious disease , active tuberculosis , Hepatitis B C , HIV . 11 . Subject state he/she active metabolic gastrointestinal disease may interfere nutrient absorption , metabolism , excretion , exclude diabetes . 12 . As determined study physician , subject take daily medication dietary supplement dos would interfere nutrient absorption , metabolism , excretion gastric motility . 13 . Subject state he/she allergy intolerance ingredient find study product .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2006</verification_date>
</DOC>